We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+8.95%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$2.13M
Cap. Flow
-$1.57M
Cap. Flow %
-0.5%
Top 10 Hldgs %
50%
Holding
82
New
21
Increased
16
Reduced
15
Closed
29

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$9.15M
2
LEGN icon
Legend Biotech
LEGN
+$8.75M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.75M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.52M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.52M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$21.4M
2
RVMD icon
Revolution Medicines
RVMD
+$11.3M
3
NUVL
Nuvalent
NUVL
+$9.55M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$9.21M
5
CGON icon
CG Oncology
CGON
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DFTX
51
Definium Therapeutics
DFTX
$5.85B
$590K 0.19%
+90,852
New +$598K
IMVT icon
52
CALL
Immunovant
IMVT
$8B
$310K 0.1%
+100,000
New +$1.51M
GERN icon
53
CALL
Geron
GERN
$911M
$52.5K 0.02%
+300,000
New +$425K
ABUS icon
54
Arbutus Biopharma
ABUS
$936M
– –
-467,882
Closed -$1.63M
ARQT icon
55
CALL
Arcutis Biotherapeutics
ARQT
$3.47B
– –
-100,000
Closed -$42.5K
ASND icon
56
Ascendis Pharma A/S
ASND
$17B
– –
-14,732
Closed -$2.3M
BBC icon
57
CALL
Virtus Biotech Clinical Trials ETF
BBC
$53.5M
– –
-132,500
Closed -$16.6K
BPMC
58
DELISTED
Blueprint Medicines
BPMC
– –
-61,927
Closed -$5.48M
CGON icon
59
CG Oncology
CGON
$6.13B
– –
-289,823
Closed -$7.1M
CVS icon
60
PUT
CVS Health
CVS
$136B
– –
-64,100
Closed -$165K
CYTK icon
61
Cytokinetics
CYTK
$10.9B
– –
-149,648
Closed -$6.01M
DYN icon
62
Dyne Therapeutics
DYN
$3.76B
– –
-84,430
Closed -$883K
ELVN icon
63
Enliven Therapeutics
ELVN
$3.63B
– –
-120,430
Closed -$2.37M
EWTX icon
64
Edgewise Therapeutics
EWTX
$4.11B
– –
-180,255
Closed -$3.97M
EWTX icon
65
PUT
Edgewise Therapeutics
EWTX
$4.11B
– –
-50,000
Closed -$238K
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
– –
-268,919
Closed -$2.19M
IFRX icon
67
InflaRx
IFRX
$281M
– –
-725,019
Closed -$740K
KALV
68
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-100,000
Closed -$32.5K
MLYS icon
69
PUT
Mineralys Therapeutics
MLYS
$2.39B
– –
-125,000
Closed -$93.8K
MRK icon
70
CALL
Merck
MRK
$315B
– –
-151,700
Closed -$8.34K
NBIX icon
71
Neurocrine Biosciences
NBIX
$17.2B
– –
-21,052
Closed -$2.33M
NVO
72
CALL
Novo Nordisk
NVO
$228B
– –
-151,700
Closed -$3.79K
OCUL icon
73
Ocular Therapeutix
OCUL
$2.01B
– –
-124,523
Closed -$913K
RVMD icon
74
Revolution Medicines
RVMD
$38.1B
– –
-318,782
Closed -$11.3M
RYTM icon
75
CALL
Rhythm Pharmaceuticals
RYTM
$7.28B
– –
-10,000
Closed -$15.5K
1 2
3
4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Stempoint Capital held 82 positions worth $312M, down 0.68% from $314M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Stempoint Capital's Q2 2025 filing shows 21 new, 16 increased, 15 reduced and 29 closed positions. Its largest new stake was Mineralys Therapeutics: 631,586 shares worth $8.55M. The largest sale was Roivant Sciences, an estimated $21.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

  • Stempoint Capital's largest Q2 2025 buy was Mineralys Therapeutics: 631,586 shares worth $8.55M.
  • Stempoint Capital added most to Rhythm Pharmaceuticals in Q2 2025, an estimated $8.75M increase.
  • Stempoint Capital's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $21.4M.
  • Stempoint Capital fully exited Revolution Medicines in Q2 2025, selling an estimated $11.3M.
  • Stempoint Capital's ten largest holdings make up 50% of its $312M portfolio in Q2 2025.
  • Stempoint Capital opened 21 new positions and closed 29 in Q2 2025.
  • Stempoint Capital's portfolio value fell 0.68% quarter-over-quarter to $312M.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.